Navigation Links
Detecting 'bath salts' designer drug

HUNTSVILLE, TX -- In October 2011 the National Institute of Justice (NIJ) and the Forensic Science Foundation (FSF) funded a capstone project proposal in the Master of Forensic Science Program at Sam Houston State University to investigate the designer drugs known as "Bath Salts" (beta-keto-amphetamines or BKAs).

Designer drugs have posed a challenge for law enforcement and forensic scientists for decades, but more recently the proliferation of analogs has overwhelmed the scientific community, in large part due to the internet. The majority of BKA designer drugs are derived from cathinone, the active ingredient of Khat (Catha edulis), a plant native to Africa and the Middle East. Synthesis of these drugs is readily accomplished by clandestine chemists, making it an appealing drug for the designer drugs market.

The study will specifically address a number of central nervous system stimulants that are capable of producing powerful and unpredictable adrenergic and hallucinogenic effects. Many of these drugs were considered "legal highs" until the Drug Enforcement Administration placed several of them in Schedule I of the Federal Controlled Substance Act in an emergency scheduling action earlier this year. These drugs were available locally in gas stations, head shops and online until September 1 of this year, when The State of Texas enacted legislation to ban these substances. At least 24 other states have outlawed them, or have legislation pending due to intense media interest and publicity.

In the SHSU study, at least six of the most popular "bath salt" drugs will be investigated in biological samples. These include mephedrone, methylone, ethylone, butylone, MDPV and naphyrone. Mephedrone is one of the most common BKAs. It has a reputation of having similar but superior effects to MDMA (3,4 -methylenedioxymethamphetamine or Ecstasy). Street names for mephedrone include MCAT, meow meow, MMC hammer, 4 MMC, bubbles, meph, rush, drone and plant feeder. Mephedrone and the related BKAs are still relatively new, so few clinical, pharmacological or toxicological studies have been reported.

These drugs are easily identified in seized drug materials. The SHSU Regional Crime Laboratory (RCL), operated by the Criminal Justice Center, routinely receives items of evidence containing these drugs. Detection in toxicological (biological) evidence is far more challenging. Toxicologists are struggling to develop methodology to detect these drugs (and their metabolites) in biological specimens. Even less is understood with respect to the interpretation of results, and this has real consequences in terms of criminal casework and death investigation.

In order for these drugs to be studied and understood, analytical methodology will be developed for routine use. In the study, solid phase extraction (SPE) will be used to isolate the beta-keto amphetamines from biological matrices. Chromatographic and spectroscopic methods will be developed for instrumental analysis of the biological extracts. Chemical derivatization will be used to develop extracts that are amenable to common instrumental techniques that are used in a crime laboratory, such as gas chromatography/mass spectrometry (GC/MS).

The study, which will be conducted by MSFS student Kayla Ellefsen and Dr. Sarah Kerrigan at RCL, is an example of the MSFS student capstone experience, whereby students must successfully complete an intensive one-year research project with a faculty member. During the final phase of the study, the optimized procedure will be validated for use in actual casework at the lab.


Contact: Beth Kuhles
Sam Houston State University

Related medicine news :

1. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
2. FDG-PET/CT plays a definite role in detecting colorectal cancer recurrences
3. Detecting tumors faster
4. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
5. Effective methods for detecting early signs of tremor
6. Colorful brains, cooling lasers, disease-detecting lights and more
7. deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer
8. Detecting esophageal cancer with light
9. New molecular imaging technologies for detecting cellular processes
10. Toward a fast, simple test for detecting cholera rampaging in 40 countries
11. Penn study suggests another avenue for detecting Alzheimers disease
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: